| Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma I Ramachandran, DE Lowther, R Dryer-Minnerly, R Wang, S Fayngerts, ... Journal for immunotherapy of cancer 7, 1-14, 2019 | 115 | 2019 |
| Clinical, pathological, and genomic features of EWSR1-PATZ1 fusion sarcoma JA Bridge, J Sumegi, M Druta, MM Bui, E Henderson-Jackson, K Linos, ... Modern Pathology 32 (11), 1593-1604, 2019 | 85 | 2019 |
| Outcomes and clinical predictors of improved survival in a patients undergoing pulmonary metastasectomy for sarcoma LA Dossett, EM Toloza, J Fontaine, LA Robinson, D Reed, M Druta, ... Journal of Surgical Oncology 112 (1), 103-106, 2015 | 51 | 2015 |
| Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial DS Hong, BA Van Tine, S Biswas, C McAlpine, ML Johnson, AJ Olszanski, ... Nature medicine 29 (1), 104-114, 2023 | 43 | 2023 |
| Metabolic syndrome and colorectal cancer: is hyperinsulinemia/insulin receptor-mediated angiogenesis a critical process? JJ Liu, M Druta, D Shibata, D Coppola, I Boler, A Elahi, RR Reich, ... Journal of geriatric oncology 5 (1), 40-48, 2014 | 40 | 2014 |
| Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution JF Helm, BA Centen, D Coppola, M Druta, JY Park, DT Chen, PJ Hodul, ... Cancer Control 15 (4), 288-294, 2008 | 40 | 2008 |
| Pexidartinib long‐term hepatic safety profile in patients with tenosynovial giant cell tumors JH Lewis, H Gelderblom, M Sande, S Stacchiotti, JH Healey, WD Tap, ... The oncologist 26 (5), e863-e873, 2021 | 36 | 2021 |
| Practical issues for retroperitoneal sarcoma V Pham, E Henderson-Jackson, MP Doepker, JT Caracciolo, ... Cancer Control 23 (3), 249-264, 2016 | 29 | 2016 |
| Clinical utility of genomic profiling in the treatment of advanced sarcomas: a single-center experience S Boddu, CM Walko, S Bienasz, MM Bui, E Henderson-Jackson, ... JCO Precision Oncology 2, 1-8, 2018 | 28 | 2018 |
| A phase 1b study evaluating the safety, tolerability, and immunogenicity of CMB305, a lentiviral-based prime-boost vaccine regimen, in patients with locally advanced, relapsed … N Somaiah, SP Chawla, MS Block, JC Morris, K Do, JW Kim, M Druta, ... Oncoimmunology 9 (1), 1847846, 2020 | 27 | 2020 |
| Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259t in HLA-A2+ patients with synovial sarcoma … C Mackall, WD Tap, J Glod, M Druta, WA Chow, DM Araujo, SA Grupp, ... Journal of Clinical Oncology 35 (15_suppl), 3000-3000, 2017 | 23 | 2017 |
| Measuring quality of care in the treatment of colorectal cancer: The Moffitt Quality Practice Initiative PB Jacobsen, D Shibata, EM Siegel, M Druta, JH Lee, J Marshburn, ... Journal of oncology practice 3 (2), 60-65, 2007 | 23 | 2007 |
| Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS). N Somaiah, SP Chawla, MS Block, JC Morris, KT Do, JW Kim, M Druta, ... Journal of Clinical Oncology 35 (15_suppl), 11006-11006, 2017 | 20 | 2017 |
| 298 Final analysis of the phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial … S D’Angelo, G Demetri, B Van Tine, M Druta, J Glod, W Chow, N Pandya, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 18 | 2020 |
| Pilot study of NY-ESO-1c259 T cells in advanced myxoid/round cell liposarcoma. SP D'Angelo, M Druta, DA Liebner, S Schuetze, N Somaiah, BA Van Tine, ... Journal of Clinical Oncology 36 (15_suppl), 3005-3005, 2018 | 18 | 2018 |
| Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma A Gyurdieva, S Zajic, YF Chang, EA Houseman, S Zhong, J Kim, ... Nature communications 13 (1), 5296, 2022 | 17 | 2022 |
| Case of pembrolizumab-induced myocarditis presenting as torsades de pointes with safe re-challenge DH Lee, M Armanious, J Huang, D Jeong, M Druta, MG Fradley Journal of Oncology Pharmacy Practice 26 (6), 1544-1548, 2020 | 17 | 2020 |
| Primary efficacy and safety of letetresgene autoleucel (lete-cel; GSK3377794) pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS). SP D'Angelo, M Druta, BA Van Tine, DA Liebner, S Schuetze, ... Journal of Clinical Oncology 40 (16_suppl), 11500-11500, 2022 | 12 | 2022 |
| Results of treating primary pulmonary sarcomas and pulmonary carcinosarcomas LA Robinson, NA Babacan, T Tanvetyanon, E Henderson-Jackson, ... The Journal of Thoracic and Cardiovascular Surgery 162 (1), 274-284, 2021 | 12 | 2021 |
| SPEARHEAD-1: A phase II trial of ADP-A2M4 SPEAR T cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma. DM Araujo, M Druta, M Agulnik, SP D'Angelo, JY Blay, SJ Strauss, ... Journal of Clinical Oncology 38 (15_suppl), TPS11569-TPS11569, 2020 | 11 | 2020 |
